Taken together, extensive in vitro and in vivo analyses support the further evaluation of YTX-7739 as an SCD inhibitor for the treatment of Parkinson’s disease and provides evidence for key relationships among α-synuclein, lipid biology, and stearoyl-CoA desaturase. This evidence concerns the gene SNCA and Parkinson disease.